Comparative Pharmacology
Head-to-head clinical analysis: FREAMINE III 10 versus FREAMINE III 8 5.
Peer-Reviewed Evidence
Head-to-head clinical analysis: FREAMINE III 10 versus FREAMINE III 8 5.
FREAMINE III 10% vs FREAMINE III 8.5%
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
FREAMINE III 10% is a parenteral amino acid solution that provides essential and non-essential amino acids for protein synthesis and nitrogen balance in patients unable to tolerate oral or enteral nutrition.
FREAMINE III 8.5% is a crystalline amino acid solution that provides essential and non-essential amino acids for protein synthesis, nitrogen balance maintenance, and tissue repair. It acts as a substrate for protein anabolism in patients unable to tolerate adequate oral or enteral intake.
Intravenous administration as part of parenteral nutrition. Typical adult dose: 0.8-1.5 g amino acids/kg/day, infused continuously over 24 hours.
Intravenous infusion; typical adult dose is 0.8-1.5 g amino acids/kg/day (equivalent to 9.4-17.6 mL/kg/day of Freamine III 8.5%). Initiate at lower end and titrate to metabolic needs. Administer via central or peripheral line with dextrose and electrolytes as part of parenteral nutrition.
None Documented
None Documented
Component-dependent: free amino acids t1/2 ~15–30 min; urea cycle intermediates ca. 2 h.
Terminal elimination half-life of infused amino acids is approximately 15-30 minutes for most, but albumin synthesis half-life is 20-22 days; clinical context: continuous infusion needed for nitrogen balance.
Primarily renal; amino acids and nitrogenous waste products are excreted as urea and other metabolites. <5% fecal.
Renal: 90-95% of infused amino acids are reabsorbed; excess nitrogen excreted as urea (80-90% of nitrogen load) and ammonia (<10%). Biliary/fecal: negligible (<5%).
Category C
Category C
Parenteral nutrition amino acid
Parenteral nutrition amino acid